193 related articles for article (PubMed ID: 33012191)
1. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors.
Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J
Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191
[No Abstract] [Full Text] [Related]
2. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
[TBL] [Abstract][Full Text] [Related]
4. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
[TBL] [Abstract][Full Text] [Related]
8. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
[TBL] [Abstract][Full Text] [Related]
11. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
[TBL] [Abstract][Full Text] [Related]
12. Design of Selective PARP-1 Inhibitors and Antitumor Studies.
Zhang Y; Li X; Liu F; Bai X; Liu X; Sun H; Gao C; Lin Y; Xing P; Zhu J; Liu R; Wang Z; Dai J; Shi D
J Med Chem; 2024 Jun; 67(11):8877-8901. PubMed ID: 38776379
[TBL] [Abstract][Full Text] [Related]
13. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Kerrigan F; Loh VM; Martin NM; Menear KA; Smith GC
Bioorg Med Chem Lett; 2006 Feb; 16(4):1040-4. PubMed ID: 16290932
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold.
Elmasry GF; Aly EE; Awadallah FM; El-Moghazy SM
Bioorg Chem; 2019 Jun; 87():655-666. PubMed ID: 30952061
[TBL] [Abstract][Full Text] [Related]
15. Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.
Li S; Li XY; Zhang TJ; Zhu J; Liu KL; Wang DP; Meng FH
Bioorg Chem; 2021 Jun; 111():104840. PubMed ID: 33780687
[TBL] [Abstract][Full Text] [Related]
16. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lin C; Liu C; Hu P; Zou Z; Sun G
Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Quinazoline-2,4(1
Zhou J; Ji M; Wang X; Zhao H; Cao R; Jin J; Li Y; Chen X; Sheng L; Chen X; Xu B
J Med Chem; 2021 Nov; 64(22):16711-16730. PubMed ID: 34748333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]